obesity
Everything filed under metabolic in our medical research coverage, the 3 reports filed on it so far.
Moonwalk Biosciences pivots to RNAi obesity drugs with $70M
Moonwalk Biosciences has raised $70 million in Series B funding to advance a pipeline of RNA interference drugs for obesity.
Obesity Medicines Are Disruptive Innovation
A commentary in Nature Medicine argues that new anti-obesity drugs represent a disruptive innovation requiring health system adaptation.
Novo Nordisk CEO Warns of Growing Competition in Obesity Drug Market
Novo Nordisk's CEO believes investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like...